168 related articles for article (PubMed ID: 23244822)
1. What is wrong with orphan drug policies? Suggestions for ways forward.
Kanavos P; Nicod E
Value Health; 2012 Dec; 15(8):1182-4. PubMed ID: 23244822
[TBL] [Abstract][Full Text] [Related]
2. What is wrong with orphan drug policies?
Côté A; Keating B
Value Health; 2012 Dec; 15(8):1185-91. PubMed ID: 23244823
[TBL] [Abstract][Full Text] [Related]
3. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
4. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
5. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
6. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
7. [Orphan drugs].
Kolár J; Chalabala M; Srámková H
Ceska Slov Farm; 2001 Mar; 50(2):59-65. PubMed ID: 11288591
[TBL] [Abstract][Full Text] [Related]
8. Economic considerations in the provision of treatments for rare diseases.
McCabe C; Edlin R; Round J
Adv Exp Med Biol; 2010; 686():211-22. PubMed ID: 20824448
[TBL] [Abstract][Full Text] [Related]
9. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
10. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
11. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
12. Evaluating and improving orphan drug regulations in Europe: a Delphi policy study.
Picavet E; Cassiman D; Simoens S
Health Policy; 2012 Nov; 108(1):1-9. PubMed ID: 22989856
[TBL] [Abstract][Full Text] [Related]
13. The economics of orphan drug policy in the US. Can the legislation be improved?
Peabody JW; Ruby A; Cannon P
Pharmacoeconomics; 1995 Nov; 8(5):374-84. PubMed ID: 10160072
[TBL] [Abstract][Full Text] [Related]
14. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
15. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
16. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act.
Arno PS; Bonuck K; Davis M
Milbank Q; 1995; 73(2):231-52. PubMed ID: 7776947
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceuticals. Adopt an orphan.
Karr A
Health Serv J; 1999 Nov; 109(5681):28. PubMed ID: 10724720
[No Abstract] [Full Text] [Related]
18. [Orphan Drugs: Underrated Opportunities for The Developers in Europe].
Tillet Y; Maillols-Perroy AC
Therapie; 2015; 70(4):351-7. PubMed ID: 25997721
[TBL] [Abstract][Full Text] [Related]
19. CMS move threatens to put orphan drugs out in cold.
Carroll J
Manag Care; 2003 Jul; 12(7):10-1. PubMed ID: 12891947
[No Abstract] [Full Text] [Related]
20. Orphan drugs: the regulatory environment.
Franco P
Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]